肌缩侧面硬化症 (ALS) 感觉神经元功能障碍的特征:对ALS治疗的潜力
Soju Seki1, Yoshihiro Kitaoka1, Sou Kawata1
1Department of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Osaka University, 1-8 Yamadaoka, Suita 565-0871, Osaka, Japan.
Biomedicines
|November 25, 2023
概括
感觉神经元,而不仅仅是运动神经元,都与肌缩侧面硬化症 (ALS) 有关. 研究揭示了ALS患者的感觉神经元功能障碍,这表明这种神经退行性疾病的新治疗点.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 遗传学 是一个遗传学.
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种神经退行性疾病,主要影响运动神经元.
- 新出现的证据表明,感官神经元参与ALS病理学.
- 目前的ALS治疗方法是无效的,强调了需要新的治疗策略.
研究的目的:
- 综合审查与ALS相关的感觉神经元功能障碍.
- 探索ALS感官神经元参与的临床表现和潜在机制.
- 讨论针对感觉神经元的潜在潜力,用于新的ALS疗法.
主要方法:
- 对ALS患者感官症状和神经传导研究的临床研究的综述.
- 对经神经活检的组织学发现进行分析.
- 检查ALS模型感官神经元中遗传异常和蛋白质聚合的临床前研究.
主要成果:
- 30%的ALS患者表现出感官症状和异常的感官神经传导.
- 90%的ALS患者在经神经活检中表现出组织学异常.
- 在感官神经元中发现了遗传异常和TAR DNA结合蛋白43聚合.
结论:
- 感觉神经元功能障碍是ALS的一个重要,但被低估的方面.
- 亲感感官神经元可能在运动控制和ALS发病过程中发挥作用.
- 针对感觉神经元,特别是感知途径,为未来的ALS疗法提供了有希望的途径.
相关概念视频
Parkinson's Disease: Overview
557
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
557
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Parkinson's Disease: Treatment
276
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
276


